Technical Analysis for MYGN - Myriad Genetics, Inc.

Grade Last Price % Change Price Change
grade F 27.42 -0.72% -0.20
MYGN closed down 0.72 percent on Friday, September 13, 2019, on 78 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical MYGN trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
New Uptrend Bullish 0.00%
Weak + Overbought Other 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.72%
Pocket Pivot Bullish Swing Setup -0.72%
Weak + Overbought Other -0.72%
Above Upper BB Strength -0.72%
Overbought Stochastic Strength -0.72%

Older signals for MYGN ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of predictive medicine, personalized medicine, and prognostic medicine tests primarily in the United States. The company's molecular diagnostic tests are designed to analyze genes, their mutations, expression levels, and proteins to assess an individual's risk for developing disease later in life; determine a patient's likelihood of responding to a particular drug; and assess a patient's risk of disease progression and disease recurrence. It offers various molecular diagnostic tests that include BRACAnalysis and BART, which are predictive medicine tests for hereditary breast and ovarian cancer; COLARIS predictive medicine test for hereditary colorectal and uterine cancer; COLARIS AP predictive medicine test for hereditary colorectal cancer; MELARIS predictive medicine test for hereditary melanoma; PANEXIA, a predictive medicine test for pancreatic cancer; PREZEON, a personalized and prognostic medicine test for cancer; Prolaris, a prognostic medicine test for prostate cancer; and TheraGuide 5-FU, a personalized medicine test for drug toxicity. The company, through its subsidiary, Myriad RBM, Inc., also offers biomarker discovery and companion diagnostic services to the pharmaceutical, biotechnology, and medical research industries that include multi-analyte profile testing services; multiplexed immunoassay kits; and TruCulture, a self-contained whole blood culture that allows pharmaceutical and biotechnology companies to identify drug toxicity prior to human trials. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.
Medicine Biotechnology Cancer Clinical Medicine Disease Prostate Cancer Ovarian Cancer Medical Genetics Diagnostic Tests Pancreatic Cancer Biomarkers Chemical Pathology Personalized Medicine
Is MYGN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 48.77
52 Week Low 22.04
Average Volume 1,376,526
200-Day Moving Average 29.4216
50-Day Moving Average 29.3334
20-Day Moving Average 24.397
10-Day Moving Average 25.135
Average True Range 1.7662
ADX 25.57
+DI 26.9511
-DI 26.1091
Chandelier Exit (Long, 3 ATRs ) 24.0514
Chandelier Exit (Short, 3 ATRs ) 27.3386
Upper Bollinger Band 27.5165
Lower Bollinger Band 21.2775
Percent B (%b) 0.98
BandWidth 25.572816
MACD Line -1.1111
MACD Signal Line -1.7827
MACD Histogram 0.6716
Fundamentals Value
Market Cap 1.88 Billion
Num Shares 68.6 Million
EPS 0.32
Price-to-Earnings (P/E) Ratio 85.69
Price-to-Sales 3.01
Price-to-Book 2.98
PEG Ratio 3.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 29.04
Resistance 3 (R3) 29.05 28.51 28.77
Resistance 2 (R2) 28.51 28.10 28.51 28.68
Resistance 1 (R1) 27.97 27.85 27.70 27.96 28.59
Pivot Point 27.43 27.43 27.30 27.43 27.43
Support 1 (S1) 26.89 27.02 26.62 26.88 26.25
Support 2 (S2) 26.35 26.77 26.35 26.16
Support 3 (S3) 25.81 26.35 26.07
Support 4 (S4) 25.80